John Rose, MD
Neurology · Salt Lake City, UTNPI 1912947086
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Novartis accounts for 66.3% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $1,190 and has fallen 85.0% since, to $179 in 2025.
Across 34 payments — averaging $78.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- TG Therapeutics, Inc.$340
- Biogen$192
- AbbVie$125
- Sanofi$125
- EMD Serono, Inc.$99
- plus $22 from 1 others
Across 29 payments — averaging $2048.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$43K
- F. Hoffmann-la Roche AG$17K
What the payments were for
- Food & beverage$2,60097%
- Gifts$773%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 22 | $1,776 |
| TG Therapeutics, Inc. | 4 | $340 |
| Biogen | 3 | $192 |
| AbbVie | 1 | $125 |
| Sanofi | 1 | $125 |
| EMD Serono, Inc. | 2 | $99 |
| Avanir Pharmaceuticals, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,677 in reported general payments places this provider in the 60th percentile of 157 neurology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 24 | $262,505 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 12 | $96,627 |
| CopaxoneGlatiramer Acetate | 13 | $70,504 |
| Dimethyl Fumarate | 56 | $58,113 |
| Glatiramer Acetate | 27 | $43,560 |
| GlatopaGlatiramer Acetate | 17 | $28,983 |
| MyrbetriqMirabegron | 21 | $18,146 |
| Dalfampridine ErDalfampridine | 34 | $16,121 |
| Emgality PenGalcanezumab-Gnlm | 14 | $9,949 |
| GemtesaVibegron | 12 | $5,831 |
| Baclofen | 98 | $3,939 |
| Gabapentin | 102 | $2,333 |
| Methenamine Hippurate | 16 | $1,852 |
| Solifenacin Succinate | 39 | $1,507 |
| Modafinil | 38 | $1,452 |
Paid to pharmacies, not to this prescriber.
Other neurology in Salt Lake City
- Timothy WestSalt Lake City$856K
- Stacey SteevesSalt Lake City$548K
- Amir ArainSalt Lake City$329K
- Mark BrombergSalt Lake City$265K
- April ErwinSalt Lake City$263K
- Albert SmithSalt Lake City$122K
- John FoleySalt Lake City$99K
- Kevin BrennanSalt Lake City$81K
- Lucy DewittSalt Lake City$81K
- Nicholas JohnsonSalt Lake City$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.